董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Silviu Itescu | 男 | Chief Executive Officer and Director | 67 | 未披露 | 6999.14 | 2023-08-31 |
| Eric Rose | 男 | Chief Medical Officer and Director | 73 | 未披露 | 11.33 | 2023-08-31 |
| Michael Spooner | 男 | Director | 67 | 未披露 | 112.67 | 2023-08-31 |
| Joseph Swedish | 男 | Chairman of the Board | -- | 未披露 | 40.00 | 2023-08-31 |
| Philip Facchina | 男 | Director | -- | 未披露 | 未持股 | 2023-08-31 |
| Philip Krause | 男 | Director | -- | 未披露 | 未持股 | 2023-08-31 |
| Jane Bell | 女 | Director | -- | 未披露 | 未持股 | 2023-08-31 |
| William Burns | 男 | Director | 76 | 未披露 | 17.63 | 2023-08-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dagmar Rosa Bjorkeson | 女 | Chief Operating Officer | 60 | 未披露 | 未持股 | 2023-08-31 |
| Silviu Itescu | 男 | Chief Executive Officer and Director | 67 | 未披露 | 6999.14 | 2023-08-31 |
| Eric Rose | 男 | Chief Medical Officer and Director | 73 | 未披露 | 11.33 | 2023-08-31 |
| Peter Howard | 男 | General Counsel | 56 | 未披露 | 未持股 | 2023-08-31 |
| Michael Schuster | 男 | Pharma Partnering | 47 | 未披露 | 未持股 | 2023-08-31 |
| Paul Simmons | 男 | Scientific Advisor to the Chief Executive Officer | 65 | 未披露 | 未持股 | 2023-08-31 |
| Geraldine Storton | 女 | Head of Regulatory Affairs and Quality Management | -- | 未披露 | 未持股 | 2023-08-31 |
| Andrew Chaponnel | 男 | Interim Chief Financial Officer | -- | 未披露 | 未持股 | 2023-08-31 |
| Justin Horst | 男 | Head of Manufacturing | -- | 未披露 | 未持股 | 2023-08-31 |
| Niva Sivakumar | 女 | Secretary | -- | 未披露 | 未持股 | 2023-08-31 |
| Paul Hughes | 男 | Secretary | -- | 未披露 | 未持股 | 2023-08-31 |
董事简历
中英对照 | 中文 | 英文- Silviu Itescu
-
Silviu Itescu，他是Mesoblast Limited的首席执行官。他曾一直任职于Mesoblast Limited的董事会（2004年Mesoblast Limited创立以来），也曾担任执行董事（2007年至2011年），并于2011年成为首席执行官兼董事总经理。2004年创立Mesoblast公司之前，他曾创立医生科学家在干细胞生物学、自身免疫性疾病、器官移植和心脏衰竭领域的国际声誉。他一直任教于Columbia University（位于纽约）、澳大利亚墨尔本莫纳什大学。他于2011年被誉为“BioSpectrum Asia Person of the Year”。他于2013年获得the Vatican’s Pontifical Council for Culture的就职关键创新者奖，因为他在科学和临床医学转化与成人干细胞疗法的领导。
Silviu Itescu,has served on the Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, Dr. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, Dr. Itescu was named BioSpectrum Asia Person of the Year. Dr. Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies. - Silviu Itescu，他是Mesoblast Limited的首席执行官。他曾一直任职于Mesoblast Limited的董事会（2004年Mesoblast Limited创立以来），也曾担任执行董事（2007年至2011年），并于2011年成为首席执行官兼董事总经理。2004年创立Mesoblast公司之前，他曾创立医生科学家在干细胞生物学、自身免疫性疾病、器官移植和心脏衰竭领域的国际声誉。他一直任教于Columbia University（位于纽约）、澳大利亚墨尔本莫纳什大学。他于2011年被誉为“BioSpectrum Asia Person of the Year”。他于2013年获得the Vatican’s Pontifical Council for Culture的就职关键创新者奖，因为他在科学和临床医学转化与成人干细胞疗法的领导。
- Silviu Itescu,has served on the Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, Dr. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, Dr. Itescu was named BioSpectrum Asia Person of the Year. Dr. Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies.
- Eric Rose
-
Eric Rose，他一直担任Mesoblast Limited的董事（2013年以来）。他目前是SIGA Technologies公司的董事长兼首席执行官，以及MacAndrews & Forbes公司（Ronald O. Perelman的控股公司）的生命科学执行副总裁。从2008年到2012年，他曾担任古根海姆教授，以及the Mount Sinai School of Medicine的健康证据和政策部门的主席。1994年至2007年，他曾担任纽约长老会医院的哥伦比亚长老会医学中心（the Columbia Presbyterian Center of New York Presbyterian Hospital）的手术部门主席和外科医生。1982年至1992年，他曾领导纽约长老会医院的哥伦比亚长老会医学中心（Columbia Presbyterian）的美国心脏移植项目。他目前任职于ABIOMED公司的董事会。
Eric Rose,is a highly respected physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As a world-renowned heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first successful pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon-in-Chief of Columbia Presbyterian Medical Center in New York. During this time his leadership of the NIH supported program Randomized Evaluation of Mechanical Circulatory Support in Heart Failure (REMATCH) resulted in the first FDA approval of an implantable left ventricular assist device for long term circulatory support, spawning an entire new industry. From 2007-2011, Dr. Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and emerging diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he oversaw development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr. Rose played a key role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). Dr. Rose's tenure on the ABIOMED board ended in December 2022 with the sale of the company to Johnson & Johnson for $17.7 billion. - Eric Rose，他一直担任Mesoblast Limited的董事（2013年以来）。他目前是SIGA Technologies公司的董事长兼首席执行官，以及MacAndrews & Forbes公司（Ronald O. Perelman的控股公司）的生命科学执行副总裁。从2008年到2012年，他曾担任古根海姆教授，以及the Mount Sinai School of Medicine的健康证据和政策部门的主席。1994年至2007年，他曾担任纽约长老会医院的哥伦比亚长老会医学中心（the Columbia Presbyterian Center of New York Presbyterian Hospital）的手术部门主席和外科医生。1982年至1992年，他曾领导纽约长老会医院的哥伦比亚长老会医学中心（Columbia Presbyterian）的美国心脏移植项目。他目前任职于ABIOMED公司的董事会。
- Eric Rose,is a highly respected physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As a world-renowned heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first successful pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon-in-Chief of Columbia Presbyterian Medical Center in New York. During this time his leadership of the NIH supported program Randomized Evaluation of Mechanical Circulatory Support in Heart Failure (REMATCH) resulted in the first FDA approval of an implantable left ventricular assist device for long term circulatory support, spawning an entire new industry. From 2007-2011, Dr. Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and emerging diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he oversaw development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr. Rose played a key role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). Dr. Rose's tenure on the ABIOMED board ended in December 2022 with the sale of the company to Johnson & Johnson for $17.7 billion.
- Michael Spooner
-
Michael Spooner，他一直担任Mesoblast Limited的董事（2004年以来）。期间，他担任多种职务，包括董事长（从2004年Mesoblast Limited首次公开募股到2007年）、审计和风险委员会主席，以及Mesoblast Limited的薪酬委员会的成员。过去的几年中，他曾任职于几个澳大利亚和国际生物技术公司的董事会，担任多种职务，其中包括BiVacor Pty Ltd （2009年至2013年）、Advanced Surgical Design & Manufacture Limited （2010年至2011年）、Peplin, Inc. （2004年至2009年）、Hawaii Biotech, Inc. （2010年至2012年）、Hunter Immunology Limited （2007年至2008年）、Ventracor Limited （2001年至2003年）。2001年重回澳大利亚之前，他曾花费职业生涯的大部分时间在国际事务上，在那里他曾担任多种职务，包括PA Consulting Group（英国管理咨询公司）的合伙人、PricewaterhouseCoopers （Coopers & Lybrand，位于香港）的首席合伙人兼咨询服务董事。此外，他曾拥有并运营国际公司，并提供服务，也曾咨询多个美国和亚洲的上市公司。
Michael Spooner,has served on the Board of Directors since 2004. During this period he has filled various roles including as Chairman from the date of the ASX public listing in 2004 until 2007, Chair of the Audit and Risk Committee as well as a member of the Remuneration Committee . Over the past several years Mr. Spooner has served on the board of directors in various capacities at several Australian and international biotechnology companies, including BiVacor Pty Ltd (2009-2013), Advanced Surgical Design & Manufacture Limited (2010-2011), Peplin, Inc. (2004-2009), Hawaii Biotech, Inc. (2010-2012), Hunter Immunology Limited (2007-2008), and Ventracor Limited (2001-2003). He has been the Chairman of Simavita Ltd since May 2016 and Chairman of MicrofluidX since February 2018. Prior to returning to Australia in 2001, he spent much of his career internationally where he served in various roles including as a partner to PA Consulting Group, a UK-based management consultancy, and a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong. In addition Mr Spooner has owned and operated several international companies providing services and has consulted to a number of American and Asian public companies. - Michael Spooner，他一直担任Mesoblast Limited的董事（2004年以来）。期间，他担任多种职务，包括董事长（从2004年Mesoblast Limited首次公开募股到2007年）、审计和风险委员会主席，以及Mesoblast Limited的薪酬委员会的成员。过去的几年中，他曾任职于几个澳大利亚和国际生物技术公司的董事会，担任多种职务，其中包括BiVacor Pty Ltd （2009年至2013年）、Advanced Surgical Design & Manufacture Limited （2010年至2011年）、Peplin, Inc. （2004年至2009年）、Hawaii Biotech, Inc. （2010年至2012年）、Hunter Immunology Limited （2007年至2008年）、Ventracor Limited （2001年至2003年）。2001年重回澳大利亚之前，他曾花费职业生涯的大部分时间在国际事务上，在那里他曾担任多种职务，包括PA Consulting Group（英国管理咨询公司）的合伙人、PricewaterhouseCoopers （Coopers & Lybrand，位于香港）的首席合伙人兼咨询服务董事。此外，他曾拥有并运营国际公司，并提供服务，也曾咨询多个美国和亚洲的上市公司。
- Michael Spooner,has served on the Board of Directors since 2004. During this period he has filled various roles including as Chairman from the date of the ASX public listing in 2004 until 2007, Chair of the Audit and Risk Committee as well as a member of the Remuneration Committee . Over the past several years Mr. Spooner has served on the board of directors in various capacities at several Australian and international biotechnology companies, including BiVacor Pty Ltd (2009-2013), Advanced Surgical Design & Manufacture Limited (2010-2011), Peplin, Inc. (2004-2009), Hawaii Biotech, Inc. (2010-2012), Hunter Immunology Limited (2007-2008), and Ventracor Limited (2001-2003). He has been the Chairman of Simavita Ltd since May 2016 and Chairman of MicrofluidX since February 2018. Prior to returning to Australia in 2001, he spent much of his career internationally where he served in various roles including as a partner to PA Consulting Group, a UK-based management consultancy, and a Principal Partner and Director of Consulting Services with PricewaterhouseCoopers (Coopers & Lybrand) in Hong Kong. In addition Mr Spooner has owned and operated several international companies providing services and has consulted to a number of American and Asian public companies.
- Joseph Swedish
-
2013年至2018年，Joseph Swedish担任Anthem，Inc.董事长、总裁兼首席执行官，随后担任高级顾问（2018年至2020年）。Anthem，Inc.是美国领先的健康福利提供者。在加入Anthem，Inc.之前，瑞典人曾担任Trinity Health和Centura Health等几个主要综合梦百合提供系统的首席执行官。目前，他是IBM公司、CDW Corporation和Centrexion Therapeutics公司的董事。瑞典人是杜克大学福库商学院（Duke University&8217；s Fuqua School of Business Board of Visitors）的前任主席，也是现任成员。此前，他曾担任Catholic Health Association、America&8217；s Health Insurance Plans（AHIP）的主席。Swedish先生在北卡罗来纳大学夏洛特分校（University of North Carolina at Charlotte）获得学士学位，并在杜克大学（Duke University）获得卫生管理硕士学位。
Joseph Swedish,has more than two decades of healthcare leadership experience as the CEO for major United States healthcare enterprises. Most recently, he has served as Executive Chairman, President and CEO of Anthem Inc., America's leading health benefits provider. For 12 consecutive years, Modern Healthcare named Mr Swedish as one of the 100 Most Influential People in Healthcare, ranking in the top 20 of the health sector's most senior level executives, high-level government administrators, elected officials, academics, and thought leaders for five consecutive years. Prior to joining Anthem, Mr. Swedish was CEO for several major integrated healthcare delivery systems, including Trinity Health and Colorado's Centura Health. He has been a Mesoblast board member since June 2018, and also serves on the boards of IBM Corporation, CDW Corporation, and Centrexion Therapeutics. Mr. Swedish is a member of Duke University's Fuqua School of Business Board of Visitors. Previously, he was Chairman of the Catholic Health Association. Mr. Swedish received a bachelor's degree from the University of North Carolina and his master's degree in health administration from Duke University. - 2013年至2018年，Joseph Swedish担任Anthem，Inc.董事长、总裁兼首席执行官，随后担任高级顾问（2018年至2020年）。Anthem，Inc.是美国领先的健康福利提供者。在加入Anthem，Inc.之前，瑞典人曾担任Trinity Health和Centura Health等几个主要综合梦百合提供系统的首席执行官。目前，他是IBM公司、CDW Corporation和Centrexion Therapeutics公司的董事。瑞典人是杜克大学福库商学院（Duke University&8217；s Fuqua School of Business Board of Visitors）的前任主席，也是现任成员。此前，他曾担任Catholic Health Association、America&8217；s Health Insurance Plans（AHIP）的主席。Swedish先生在北卡罗来纳大学夏洛特分校（University of North Carolina at Charlotte）获得学士学位，并在杜克大学（Duke University）获得卫生管理硕士学位。
- Joseph Swedish,has more than two decades of healthcare leadership experience as the CEO for major United States healthcare enterprises. Most recently, he has served as Executive Chairman, President and CEO of Anthem Inc., America's leading health benefits provider. For 12 consecutive years, Modern Healthcare named Mr Swedish as one of the 100 Most Influential People in Healthcare, ranking in the top 20 of the health sector's most senior level executives, high-level government administrators, elected officials, academics, and thought leaders for five consecutive years. Prior to joining Anthem, Mr. Swedish was CEO for several major integrated healthcare delivery systems, including Trinity Health and Colorado's Centura Health. He has been a Mesoblast board member since June 2018, and also serves on the boards of IBM Corporation, CDW Corporation, and Centrexion Therapeutics. Mr. Swedish is a member of Duke University's Fuqua School of Business Board of Visitors. Previously, he was Chairman of the Catholic Health Association. Mr. Swedish received a bachelor's degree from the University of North Carolina and his master's degree in health administration from Duke University.
- Philip Facchina
-
Philip Facchina，于2021年3月29日获委任为董事会非执行董事。Facchina先生在多个行业（包括医疗保健）的企业战略、资本市场、金融和业务发展方面拥有超过35年的经验。自2018年以来，Facchina先生一直担任SurgCenter Development的首席战略官，该公司是美国最大的非卧床手术中心私人运营商，负责监督该公司的战略关系，包括其与广泛的美国ASC市场、某些医院系统和其他市场组成部分的关系。在加入SurgCenter之前，他在公共和私人资本市场工作了20年，在那里他管理流动性和流动性差的投资组合，管理股票和债务的公共和私人资本交易，领导并购和包括私有化在内的特殊咨询过程。从2008年到2017年，Facchina先生担任机构投资管理公司Ramsey Asset Management的合伙人、联席投资组合经理和首席运营官，从1998年到2008年，Facchina先生领导FBR Capital Markets的技术、媒体和通信以及医疗保健投资银行集团。他目前担任Vion Corporation和Millennium Global Treasury Services的独立董事，是Johanna Foods Inc.首席执行官的顾问，在那里他领导审计委员会，他还担任New Markets Venture Partners的顾问。
Philip Facchina,Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter, overseeing the company's strategic relationships, including its relationships with the broad US ambulatory surgical center (ASC) market and its constituents. Prior to SurgCenter, Mr. Facchina spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take-privates. From 2008 to 2017, Mr. Facchina served as a Partner, Co-Portfolio Manager and the Chief Operating Officer of Ramsey Asset Management, an institutional investment management firm, and from 1998 to 2008 Mr. Facchina led the technology, media, and communications and healthcare investment banking groups of FBR Capital Markets. Mr. Facchina currently serves as an independent director for ViON Corporation and MilltechFX, and is Advisor to the CEO of Johanna Foods Inc, where he chairs the Audit Committee. Previously, among other directorships and committee posts, Mr. Facchina served on the Board of Web.com (Nasdaq: WEB), where he led Corporate Governance. - Philip Facchina，于2021年3月29日获委任为董事会非执行董事。Facchina先生在多个行业（包括医疗保健）的企业战略、资本市场、金融和业务发展方面拥有超过35年的经验。自2018年以来，Facchina先生一直担任SurgCenter Development的首席战略官，该公司是美国最大的非卧床手术中心私人运营商，负责监督该公司的战略关系，包括其与广泛的美国ASC市场、某些医院系统和其他市场组成部分的关系。在加入SurgCenter之前，他在公共和私人资本市场工作了20年，在那里他管理流动性和流动性差的投资组合，管理股票和债务的公共和私人资本交易，领导并购和包括私有化在内的特殊咨询过程。从2008年到2017年，Facchina先生担任机构投资管理公司Ramsey Asset Management的合伙人、联席投资组合经理和首席运营官，从1998年到2008年，Facchina先生领导FBR Capital Markets的技术、媒体和通信以及医疗保健投资银行集团。他目前担任Vion Corporation和Millennium Global Treasury Services的独立董事，是Johanna Foods Inc.首席执行官的顾问，在那里他领导审计委员会，他还担任New Markets Venture Partners的顾问。
- Philip Facchina,Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter, overseeing the company's strategic relationships, including its relationships with the broad US ambulatory surgical center (ASC) market and its constituents. Prior to SurgCenter, Mr. Facchina spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take-privates. From 2008 to 2017, Mr. Facchina served as a Partner, Co-Portfolio Manager and the Chief Operating Officer of Ramsey Asset Management, an institutional investment management firm, and from 1998 to 2008 Mr. Facchina led the technology, media, and communications and healthcare investment banking groups of FBR Capital Markets. Mr. Facchina currently serves as an independent director for ViON Corporation and MilltechFX, and is Advisor to the CEO of Johanna Foods Inc, where he chairs the Audit Committee. Previously, among other directorships and committee posts, Mr. Facchina served on the Board of Web.com (Nasdaq: WEB), where he led Corporate Governance.
- Philip Krause
-
菲利普·克劳斯，克劳斯博士在美国食品药品监督管理局拥有30多年的工作经验，在科学、监管、临床和公共卫生方面拥有独特的经验。他是一名内科和传染病委员会认证的医生，是一名研究人员，发表了100多篇有关疫苗临床评估、病毒发病机制和免疫学以及生物制品开发的论文。他目前是一名独立顾问，提供与生物产品开发有关的战略和监管咨询。他最近担任FDA疫苗研究和审查办公室副主任，领导评估生物制品以供评估和许可，并帮助监督2011-2021年期间在美国获得授权和许可的所有疫苗的开发和评估。他毕业于耶鲁大学医学院（MD）、佛罗里达州立大学（MBA）和伊利诺伊大学（计算机科学学士和硕士）。克劳斯博士在Mesoblast担任战略咨询顾问，提供监管战略方面的建议。
Philip Krause,With over 30 years of experience at the Food and Drug Administration, Dr. Krause has a unique combination of scientific, regulatory, clinical, and public health experience. He is a physician with board certification in internal medicine and infectious diseases and a researcher with over 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development. He recently served as deputy director of FDA's Office of Vaccines Research and Review, where he led assessments of biological products for evaluation and licensure and helped to oversee the development and evaluation of all vaccines authorized and licensed in the US from 2011-2021. He graduated from Yale Medical School (MD), Florida State University (MBA) and the University of Illinois (BS and MS in Computer Science). Dr Krause has a strategic advisory consulting role with Mesoblast, providing advice on regulatory strategies. - 菲利普·克劳斯，克劳斯博士在美国食品药品监督管理局拥有30多年的工作经验，在科学、监管、临床和公共卫生方面拥有独特的经验。他是一名内科和传染病委员会认证的医生，是一名研究人员，发表了100多篇有关疫苗临床评估、病毒发病机制和免疫学以及生物制品开发的论文。他目前是一名独立顾问，提供与生物产品开发有关的战略和监管咨询。他最近担任FDA疫苗研究和审查办公室副主任，领导评估生物制品以供评估和许可，并帮助监督2011-2021年期间在美国获得授权和许可的所有疫苗的开发和评估。他毕业于耶鲁大学医学院（MD）、佛罗里达州立大学（MBA）和伊利诺伊大学（计算机科学学士和硕士）。克劳斯博士在Mesoblast担任战略咨询顾问，提供监管战略方面的建议。
- Philip Krause,With over 30 years of experience at the Food and Drug Administration, Dr. Krause has a unique combination of scientific, regulatory, clinical, and public health experience. He is a physician with board certification in internal medicine and infectious diseases and a researcher with over 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development. He recently served as deputy director of FDA's Office of Vaccines Research and Review, where he led assessments of biological products for evaluation and licensure and helped to oversee the development and evaluation of all vaccines authorized and licensed in the US from 2011-2021. He graduated from Yale Medical School (MD), Florida State University (MBA) and the University of Illinois (BS and MS in Computer Science). Dr Krause has a strategic advisory consulting role with Mesoblast, providing advice on regulatory strategies.
- Jane Bell
-
Jane Bell是一名银行和金融律师，在国际律师事务所、金融服务和公司财务业务方面拥有30年的经验，专注于美国、加拿大、澳大利亚和英国的国际投资交易。她曾在多个高度监管的行业担任非执行董事，包括医疗保健、生命科学、医学研究和基金管理。贝尔女士目前担任Monash Health副主席和审计委员会主席。Monash Health是澳大利亚规模最大、最多样化的公共卫生服务机构，在医院、康复、老年护理、社区卫生和精神卫生设施的广泛网络中提供超过346万次护理。她还是Amplia Therapeutics的现任非执行董事，审计和风险委员会（ASX：ATX）主席，以及Jessie McPherson私立医院的主席。从2014年到2021年，她是澳大利亚第一家管理着超过1.2B美元资金的道德基金管理公司U Ethical的董事，也是该公司投资委员会的成员。她曾任墨尔本卫生主席，曾任哈德逊医学研究所所长。2023年，贝尔女士被任命为澳大利亚勋章（AM）成员，以表彰她对医学研究、医疗保健和非营利部门治理的重要贡献。
Jane Bell,is a banking and finance lawyer with 30 years experience in international law firms, financial services and corporate treasury operations focusing on international investment transactions in the United States, Canada, Australia and the United Kingdom. She has served as a non-executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. Ms. Bell currently serves as Deputy Chair of Monash Health and Chair of its Audit Committee, Australia's largest and most diverse public health service delivering more than 3.46 million episodes of care across an extensive network of hospitals, rehabilitation, aged care, community health and mental health facilities. She is also a current non-executive Director of Amplia Therapeutics and Chair of its Audit and Risk Committee (ASX:ATX) as well as Jessie McPherson Private Hospital. From 2014 until 2021 she was a director of U Ethical, Australia's first ethical funds manager with over $1.2B of funds under management, and a member of its Investment Committee. She is a former Chair of Melbourne Health and former director of Hudson Institute of Medical Research. In 2023, Ms Bell was appointed a Member of the Order of Australia (AM) for significant service to governance in the medical research, healthcare and not-for-profit sectors. - Jane Bell是一名银行和金融律师，在国际律师事务所、金融服务和公司财务业务方面拥有30年的经验，专注于美国、加拿大、澳大利亚和英国的国际投资交易。她曾在多个高度监管的行业担任非执行董事，包括医疗保健、生命科学、医学研究和基金管理。贝尔女士目前担任Monash Health副主席和审计委员会主席。Monash Health是澳大利亚规模最大、最多样化的公共卫生服务机构，在医院、康复、老年护理、社区卫生和精神卫生设施的广泛网络中提供超过346万次护理。她还是Amplia Therapeutics的现任非执行董事，审计和风险委员会（ASX：ATX）主席，以及Jessie McPherson私立医院的主席。从2014年到2021年，她是澳大利亚第一家管理着超过1.2B美元资金的道德基金管理公司U Ethical的董事，也是该公司投资委员会的成员。她曾任墨尔本卫生主席，曾任哈德逊医学研究所所长。2023年，贝尔女士被任命为澳大利亚勋章（AM）成员，以表彰她对医学研究、医疗保健和非营利部门治理的重要贡献。
- Jane Bell,is a banking and finance lawyer with 30 years experience in international law firms, financial services and corporate treasury operations focusing on international investment transactions in the United States, Canada, Australia and the United Kingdom. She has served as a non-executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management. Ms. Bell currently serves as Deputy Chair of Monash Health and Chair of its Audit Committee, Australia's largest and most diverse public health service delivering more than 3.46 million episodes of care across an extensive network of hospitals, rehabilitation, aged care, community health and mental health facilities. She is also a current non-executive Director of Amplia Therapeutics and Chair of its Audit and Risk Committee (ASX:ATX) as well as Jessie McPherson Private Hospital. From 2014 until 2021 she was a director of U Ethical, Australia's first ethical funds manager with over $1.2B of funds under management, and a member of its Investment Committee. She is a former Chair of Melbourne Health and former director of Hudson Institute of Medical Research. In 2023, Ms Bell was appointed a Member of the Order of Australia (AM) for significant service to governance in the medical research, healthcare and not-for-profit sectors.
- William Burns
-
William Burns，2010年3月15日，他被任命为董事会成员，现在是提名委员会、薪酬委员会和科学技术委员会成员。他给董事会带来了丰富的制药业国际销售、营销、综合和经营经验。他在罗氏（Roche）工作多年，2005至2009年，担任制药部门首席执行官和罗氏公司执行委员会成员。他担任罗氏控股公司（Roche Holdings Ltd）、基因技术公司（Genentech, Inc.）、日本中外制药公司（Chugai Pharmaceutical Co., Ltd）和Vesterfaard Frandesen的管理者，以及Masters Pharmaceuticals的主席和Biotie Therapies Corp.的副主席。此外，他担任斯特拉思克莱德大学（University of Strathclyde）惠康基金会成员和科隆大学（University of Cologne）波恩综合肿瘤学中心成员。他拥有文学士学位。
William Burns,has served on Mesoblast Limited Board of Directors since 2014 and was appointed Vice Chairman in 2016. He spent his entire management career at the Beecham Group and F. Hoffmann-La Roche Ltd. Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non-Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016. Mr Burns is also a member of the Oncology Advisory Board of the Universities of Cologne/Bonn in Germany. In 2014, he was appointed a trustee of the Institute of Cancer Research, London, and in 2016 a Governor of The Wellcome Trust in London, UK. - William Burns，2010年3月15日，他被任命为董事会成员，现在是提名委员会、薪酬委员会和科学技术委员会成员。他给董事会带来了丰富的制药业国际销售、营销、综合和经营经验。他在罗氏（Roche）工作多年，2005至2009年，担任制药部门首席执行官和罗氏公司执行委员会成员。他担任罗氏控股公司（Roche Holdings Ltd）、基因技术公司（Genentech, Inc.）、日本中外制药公司（Chugai Pharmaceutical Co., Ltd）和Vesterfaard Frandesen的管理者，以及Masters Pharmaceuticals的主席和Biotie Therapies Corp.的副主席。此外，他担任斯特拉思克莱德大学（University of Strathclyde）惠康基金会成员和科隆大学（University of Cologne）波恩综合肿瘤学中心成员。他拥有文学士学位。
- William Burns,has served on Mesoblast Limited Board of Directors since 2014 and was appointed Vice Chairman in 2016. He spent his entire management career at the Beecham Group and F. Hoffmann-La Roche Ltd. Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann-La Roche Ltd. until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non-Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016. Mr Burns is also a member of the Oncology Advisory Board of the Universities of Cologne/Bonn in Germany. In 2014, he was appointed a trustee of the Institute of Cancer Research, London, and in 2016 a Governor of The Wellcome Trust in London, UK.
高管简历
中英对照 | 中文 | 英文- Dagmar Rosa Bjorkeson
Dagmar Rosa Bjorkeson，预计将在公司完成分离之际担任Biosimilars执行副总裁和总裁。 Rosa-Bjorkeson有着20多年的行业经验，2014年加入Baxter担任生物仿制制药项目领导人。在此之前，她在Novartis Pharmaceuticals 任职17年多，担任多个职位，最近的职位是担任副总裁和Novartis Pharmaceuticals 主管。之前她曾在Novartis担任其他副总裁职位，包括担任瑞士地区主管，以及专注于销售和品牌的领导职位。加入Novartis之前，她在Forest Pharmaceutical, Ferguson Advertising 和 Hoechst-Roussell Pharmaceuticals担任多个与销售有关的职位。
Dagmar Rosa Bjorkeson,has more than 25 years of global experience in the pharmaceutical industry, including executive leadership in corporate and product strategy, market development and operational execution. She has led multiple successful product launches, including Gilenya for multiple sclerosis and Elidel for atopic eczema. During her 17 years at Novartis, Ms. Rosa-Bjorkeson was Vice President and Head of its Multiple Sclerosis Business Unit; Vice President, Business Development and Licensing in the United States; and Country Head and President for Novartis Sweden. More recently, she served as Executive Vice President and President, Biosimilars, at Baxalta, now a wholly owned subsidiary of Takeda Pharmaceutical Company. Ms. Rosa-Bjorkeson was also Executive Vice President and Chief Strategy and Development Officer at Mallinckrodt Pharmaceuticals. She holds an MBA in Marketing, an MS in Chemistry and a BS, Chemistry from the University of Texas.- Dagmar Rosa Bjorkeson，预计将在公司完成分离之际担任Biosimilars执行副总裁和总裁。 Rosa-Bjorkeson有着20多年的行业经验，2014年加入Baxter担任生物仿制制药项目领导人。在此之前，她在Novartis Pharmaceuticals 任职17年多，担任多个职位，最近的职位是担任副总裁和Novartis Pharmaceuticals 主管。之前她曾在Novartis担任其他副总裁职位，包括担任瑞士地区主管，以及专注于销售和品牌的领导职位。加入Novartis之前，她在Forest Pharmaceutical, Ferguson Advertising 和 Hoechst-Roussell Pharmaceuticals担任多个与销售有关的职位。
- Dagmar Rosa Bjorkeson,has more than 25 years of global experience in the pharmaceutical industry, including executive leadership in corporate and product strategy, market development and operational execution. She has led multiple successful product launches, including Gilenya for multiple sclerosis and Elidel for atopic eczema. During her 17 years at Novartis, Ms. Rosa-Bjorkeson was Vice President and Head of its Multiple Sclerosis Business Unit; Vice President, Business Development and Licensing in the United States; and Country Head and President for Novartis Sweden. More recently, she served as Executive Vice President and President, Biosimilars, at Baxalta, now a wholly owned subsidiary of Takeda Pharmaceutical Company. Ms. Rosa-Bjorkeson was also Executive Vice President and Chief Strategy and Development Officer at Mallinckrodt Pharmaceuticals. She holds an MBA in Marketing, an MS in Chemistry and a BS, Chemistry from the University of Texas.
- Silviu Itescu
Silviu Itescu，他是Mesoblast Limited的首席执行官。他曾一直任职于Mesoblast Limited的董事会（2004年Mesoblast Limited创立以来），也曾担任执行董事（2007年至2011年），并于2011年成为首席执行官兼董事总经理。2004年创立Mesoblast公司之前，他曾创立医生科学家在干细胞生物学、自身免疫性疾病、器官移植和心脏衰竭领域的国际声誉。他一直任教于Columbia University（位于纽约）、澳大利亚墨尔本莫纳什大学。他于2011年被誉为“BioSpectrum Asia Person of the Year”。他于2013年获得the Vatican’s Pontifical Council for Culture的就职关键创新者奖，因为他在科学和临床医学转化与成人干细胞疗法的领导。
Silviu Itescu,has served on the Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, Dr. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, Dr. Itescu was named BioSpectrum Asia Person of the Year. Dr. Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies.- Silviu Itescu，他是Mesoblast Limited的首席执行官。他曾一直任职于Mesoblast Limited的董事会（2004年Mesoblast Limited创立以来），也曾担任执行董事（2007年至2011年），并于2011年成为首席执行官兼董事总经理。2004年创立Mesoblast公司之前，他曾创立医生科学家在干细胞生物学、自身免疫性疾病、器官移植和心脏衰竭领域的国际声誉。他一直任教于Columbia University（位于纽约）、澳大利亚墨尔本莫纳什大学。他于2011年被誉为“BioSpectrum Asia Person of the Year”。他于2013年获得the Vatican’s Pontifical Council for Culture的就职关键创新者奖，因为他在科学和临床医学转化与成人干细胞疗法的领导。
- Silviu Itescu,has served on the Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, Dr. Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, Dr. Itescu was named BioSpectrum Asia Person of the Year. Dr. Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the board of directors of several publicly listed life sciences companies.
- Eric Rose
Eric Rose，他一直担任Mesoblast Limited的董事（2013年以来）。他目前是SIGA Technologies公司的董事长兼首席执行官，以及MacAndrews & Forbes公司（Ronald O. Perelman的控股公司）的生命科学执行副总裁。从2008年到2012年，他曾担任古根海姆教授，以及the Mount Sinai School of Medicine的健康证据和政策部门的主席。1994年至2007年，他曾担任纽约长老会医院的哥伦比亚长老会医学中心（the Columbia Presbyterian Center of New York Presbyterian Hospital）的手术部门主席和外科医生。1982年至1992年，他曾领导纽约长老会医院的哥伦比亚长老会医学中心（Columbia Presbyterian）的美国心脏移植项目。他目前任职于ABIOMED公司的董事会。
Eric Rose,is a highly respected physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As a world-renowned heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first successful pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon-in-Chief of Columbia Presbyterian Medical Center in New York. During this time his leadership of the NIH supported program Randomized Evaluation of Mechanical Circulatory Support in Heart Failure (REMATCH) resulted in the first FDA approval of an implantable left ventricular assist device for long term circulatory support, spawning an entire new industry. From 2007-2011, Dr. Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and emerging diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he oversaw development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr. Rose played a key role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). Dr. Rose's tenure on the ABIOMED board ended in December 2022 with the sale of the company to Johnson & Johnson for $17.7 billion.- Eric Rose，他一直担任Mesoblast Limited的董事（2013年以来）。他目前是SIGA Technologies公司的董事长兼首席执行官，以及MacAndrews & Forbes公司（Ronald O. Perelman的控股公司）的生命科学执行副总裁。从2008年到2012年，他曾担任古根海姆教授，以及the Mount Sinai School of Medicine的健康证据和政策部门的主席。1994年至2007年，他曾担任纽约长老会医院的哥伦比亚长老会医学中心（the Columbia Presbyterian Center of New York Presbyterian Hospital）的手术部门主席和外科医生。1982年至1992年，他曾领导纽约长老会医院的哥伦比亚长老会医学中心（Columbia Presbyterian）的美国心脏移植项目。他目前任职于ABIOMED公司的董事会。
- Eric Rose,is a highly respected physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As a world-renowned heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first successful pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon-in-Chief of Columbia Presbyterian Medical Center in New York. During this time his leadership of the NIH supported program Randomized Evaluation of Mechanical Circulatory Support in Heart Failure (REMATCH) resulted in the first FDA approval of an implantable left ventricular assist device for long term circulatory support, spawning an entire new industry. From 2007-2011, Dr. Rose served on the National Biodefense Scientific Board which advises the United States Health and Human Services Secretary on biodefense, influenza, and emerging diseases. In 2007 he was appointed Chairman and CEO of SIGA Technologies where he oversaw development of the first antipoxviral drug approved in the United States, TPOXX for the treatment of smallpox. Dr. Rose played a key role in obtaining FDA approval of the drug in 2019, and he was responsible for securing contracts with BARDA under which the US Government has procured 1.7 million courses of TPOXX for more than US$1billion into the Strategic National Stockpile (SNS). Dr. Rose's tenure on the ABIOMED board ended in December 2022 with the sale of the company to Johnson & Johnson for $17.7 billion.
- Peter Howard
Peter Howard，他曾一直担任Mesoblast Limited的总法律顾问和公司执行官（2011年7月以来）。他担任澳大利亚律师事务所Middletons（现称为K&L Gates）的外部法律顾问和合伙人，并一直参与Mesoblast公司（公司创立以来），以及2004年公司在澳交所上市。更普遍的是，他有着任职许多生物制药公司和大型研究机构丰富的经验，涉及公开上市、私募融资、战略、许可、知识产权和并购活动。他也担任多种职务，包括一个大型律师事务所的合伙人、企业家、董事和高管。
Peter Howard,has served as Mesoblast Limited General Counsel and Corporate Executive since July 2011. As external counsel and partner at Australian law firm, Middletons (now, K&L Gates), Mr. Howard has been integrally involved with Mesoblast since its inception and public listing on the ASX in 2004. More generally, Mr. Howard has extensive experience with many biopharmaceutical firms and major research institutions, covering public listings, private financings, strategic, licensing, intellectual property and mergers and acquisition activities. He has done so in several roles, including as a partner at a major law firm, entrepreneur, director and senior executive.- Peter Howard，他曾一直担任Mesoblast Limited的总法律顾问和公司执行官（2011年7月以来）。他担任澳大利亚律师事务所Middletons（现称为K&L Gates）的外部法律顾问和合伙人，并一直参与Mesoblast公司（公司创立以来），以及2004年公司在澳交所上市。更普遍的是，他有着任职许多生物制药公司和大型研究机构丰富的经验，涉及公开上市、私募融资、战略、许可、知识产权和并购活动。他也担任多种职务，包括一个大型律师事务所的合伙人、企业家、董事和高管。
- Peter Howard,has served as Mesoblast Limited General Counsel and Corporate Executive since July 2011. As external counsel and partner at Australian law firm, Middletons (now, K&L Gates), Mr. Howard has been integrally involved with Mesoblast since its inception and public listing on the ASX in 2004. More generally, Mr. Howard has extensive experience with many biopharmaceutical firms and major research institutions, covering public listings, private financings, strategic, licensing, intellectual property and mergers and acquisition activities. He has done so in several roles, including as a partner at a major law firm, entrepreneur, director and senior executive.
- Michael Schuster
Michael Schuster，在过去10年，他担任Mesoblast的创始执行官并担任各种执行职务。他担任Global Therapeutic Programs的执行副总裁，业务拓展董事以及运营和投资者关系副总裁。他获得塔夫斯大学（Tufts University）的本科学位，纽约医学院（New York Medical College免疫学和微生物学的博士学位和纽约福特汉姆大学（Fordham University）工商管理硕士学位。
Michael Schuster,who joined Mesoblast in 2004, leads the Group's partnering discussions. Previously he was the head of the Group's investor relations outreach program and was part of the founding executive team at both Mesoblast Limited and Angioblast Systems, Inc. Mr. Schuster was Executive Vice President of Global Therapeutic Programs from 2010 to 2013 and was the Director of Business Development and Vice President of Operations from 2004 to 2010. He holds an undergraduate degree in science from Tufts University, a Master's degree in Immunology & Microbiology from New York Medical College, and an MBA from Fordham University in New York.- Michael Schuster，在过去10年，他担任Mesoblast的创始执行官并担任各种执行职务。他担任Global Therapeutic Programs的执行副总裁，业务拓展董事以及运营和投资者关系副总裁。他获得塔夫斯大学（Tufts University）的本科学位，纽约医学院（New York Medical College免疫学和微生物学的博士学位和纽约福特汉姆大学（Fordham University）工商管理硕士学位。
- Michael Schuster,who joined Mesoblast in 2004, leads the Group's partnering discussions. Previously he was the head of the Group's investor relations outreach program and was part of the founding executive team at both Mesoblast Limited and Angioblast Systems, Inc. Mr. Schuster was Executive Vice President of Global Therapeutic Programs from 2010 to 2013 and was the Director of Business Development and Vice President of Operations from 2004 to 2010. He holds an undergraduate degree in science from Tufts University, a Master's degree in Immunology & Microbiology from New York Medical College, and an MBA from Fordham University in New York.
- Paul Simmons
Paul Simmons，他曾一直担任Mesoblast Limited的研究和开发主管（2011年以来）。他拥有近30年的干细胞研究经验，尤其是骨髓基质系统的基本造血作用和前体细胞的研究。他也曾担任the International Society of Stem Cell Research（ISSCR）的总裁（2006年至2007年）。加入Mesoblast公司之前，他曾担任the University of Texas Health的C. Harold、 Lorine G. Wallace荣誉大学校长（2008年至2011年），也曾担任the Centre for Stem Cell Research at the Brown Foundation Institute of Molecular Medicine的首届教授和董事（2006年至2011年）。他曾一直担任多个科学和医学期刊的副主编、编辑委员会成员、评论员，其中包括Experimental Hematology、Cytotherapy and Stem Cell Research、Cell Stem Cell、Stem Reports、Science and Nature。
Paul Simmons,served as Mesoblast Limited Head of Research and New Product Development since 2011 and transitioned to Scientific Advisor to the Chief Executive Officer in the current year. He has nearly 30 years of experience in stem cell research, especially research in basic hematopoiesis and in precursor cells for the stromal system of the bone marrow, and served as President of the International Society of Stem Cell Research, or ISSCR, from 2006 to 2007. Prior to joining Mesoblast, Dr. Simmons held the C. Harold and Lorine G. Wallace Distinguished University Chair at the University of Texas Health from 2008 to 2011 and served as the inaugural Professor and Director of the Centre for Stem Cell Research at the Brown Foundation Institute of Molecular Medicine from 2006 to 2011. Dr. Simmons is, or has served as, an associate editor, a member of the editorial board, or a reviewer on multiple scientific and medical journals including Experimental Hematology, Cytotherapy and Stem Cell Research, Cell Stem Cell, Stem Reports, Science and Nature.- Paul Simmons，他曾一直担任Mesoblast Limited的研究和开发主管（2011年以来）。他拥有近30年的干细胞研究经验，尤其是骨髓基质系统的基本造血作用和前体细胞的研究。他也曾担任the International Society of Stem Cell Research（ISSCR）的总裁（2006年至2007年）。加入Mesoblast公司之前，他曾担任the University of Texas Health的C. Harold、 Lorine G. Wallace荣誉大学校长（2008年至2011年），也曾担任the Centre for Stem Cell Research at the Brown Foundation Institute of Molecular Medicine的首届教授和董事（2006年至2011年）。他曾一直担任多个科学和医学期刊的副主编、编辑委员会成员、评论员，其中包括Experimental Hematology、Cytotherapy and Stem Cell Research、Cell Stem Cell、Stem Reports、Science and Nature。
- Paul Simmons,served as Mesoblast Limited Head of Research and New Product Development since 2011 and transitioned to Scientific Advisor to the Chief Executive Officer in the current year. He has nearly 30 years of experience in stem cell research, especially research in basic hematopoiesis and in precursor cells for the stromal system of the bone marrow, and served as President of the International Society of Stem Cell Research, or ISSCR, from 2006 to 2007. Prior to joining Mesoblast, Dr. Simmons held the C. Harold and Lorine G. Wallace Distinguished University Chair at the University of Texas Health from 2008 to 2011 and served as the inaugural Professor and Director of the Centre for Stem Cell Research at the Brown Foundation Institute of Molecular Medicine from 2006 to 2011. Dr. Simmons is, or has served as, an associate editor, a member of the editorial board, or a reviewer on multiple scientific and medical journals including Experimental Hematology, Cytotherapy and Stem Cell Research, Cell Stem Cell, Stem Reports, Science and Nature.
- Geraldine Storton
Geraldine Storton，她是一位经验丰富的医药高管，拥有24年以上的完整价值链经验，涉及制药和医疗器械的研究和开发、生产和全球商业化。她拥有质量和监管事务的广泛背景，最近担任细胞疗法公司的顾问。此前，她曾担任Hospira公司及其前身公司的执行职务，涉及监管事务和质量，专注于大型项目管理。她曾担任Hospira公司（位于芝加哥）的项目管理、质量副总裁，也曾领导全公司质量修复程序从而改善世界各地15处设施的生产合规。作为Commercial Quality ANZ, Asia and Japan的区域主管，她曾负责亚太国家的所有产品的质量监督和管理。她负责法规合规、批放行、现场运营、投诉管理、变更控制、尽职调查和新产品推出。作为全球监管业务主管，她负责管理新产品开发和注册、现有产品组合市场管理，涉及全球分销亚太地区所有Hospira的产品开发或制造。她于2015年12月加入Mesoblast公司。
Geraldine Storton,is a seasoned pharmaceutical executive with more than 30 years' experience across the full value chain of Pharmaceutical and Medical Device Research and Development, production and commercialization worldwide. She has an extensive background in regulatory affairs and quality, most recently as a consultant to cell therapy companies. Prior to this, Ms. Storton held executive roles at Hospira, and its predecessor companies in both regulatory affairs and quality, with a focus on major program management. As Vice President, Program Management, Quality, at Hospira headquarters in Chicago, she led a company-wide quality remediation program to improve compliance in manufacturing across 15 facilities worldwide. As Regional Director, Commercial Quality ANZ, Asia and Japan, Ms. Storton was responsible for quality oversight and management of all products sold in Asia Pacific countries. Her responsibilities included regulatory compliance, batch release, field actions, complaints management, change control, due diligence and new product launch. As director of global regulatory operations, Ms. Storton managed development and registration of new products and on-market management of the existing product portfolio for all Hospira's products developed or manufactured within Asia Pacific for global distribution. She joine Mesoblast in December 2015.- Geraldine Storton，她是一位经验丰富的医药高管，拥有24年以上的完整价值链经验，涉及制药和医疗器械的研究和开发、生产和全球商业化。她拥有质量和监管事务的广泛背景，最近担任细胞疗法公司的顾问。此前，她曾担任Hospira公司及其前身公司的执行职务，涉及监管事务和质量，专注于大型项目管理。她曾担任Hospira公司（位于芝加哥）的项目管理、质量副总裁，也曾领导全公司质量修复程序从而改善世界各地15处设施的生产合规。作为Commercial Quality ANZ, Asia and Japan的区域主管，她曾负责亚太国家的所有产品的质量监督和管理。她负责法规合规、批放行、现场运营、投诉管理、变更控制、尽职调查和新产品推出。作为全球监管业务主管，她负责管理新产品开发和注册、现有产品组合市场管理，涉及全球分销亚太地区所有Hospira的产品开发或制造。她于2015年12月加入Mesoblast公司。
- Geraldine Storton,is a seasoned pharmaceutical executive with more than 30 years' experience across the full value chain of Pharmaceutical and Medical Device Research and Development, production and commercialization worldwide. She has an extensive background in regulatory affairs and quality, most recently as a consultant to cell therapy companies. Prior to this, Ms. Storton held executive roles at Hospira, and its predecessor companies in both regulatory affairs and quality, with a focus on major program management. As Vice President, Program Management, Quality, at Hospira headquarters in Chicago, she led a company-wide quality remediation program to improve compliance in manufacturing across 15 facilities worldwide. As Regional Director, Commercial Quality ANZ, Asia and Japan, Ms. Storton was responsible for quality oversight and management of all products sold in Asia Pacific countries. Her responsibilities included regulatory compliance, batch release, field actions, complaints management, change control, due diligence and new product launch. As director of global regulatory operations, Ms. Storton managed development and registration of new products and on-market management of the existing product portfolio for all Hospira's products developed or manufactured within Asia Pacific for global distribution. She joine Mesoblast in December 2015.
- Andrew Chaponnel
Andrew Chaponnel拥有约25年的财务经验，包括在Mesoblast工作9年，最初担任集团财务总监6年，过去3年担任财务主管。作为Mesoblast Group Finance Leadership的一部分，他一直参与执行和维护我们的借款安排，各种战略合作伙伴关系，股权配售，纳斯达克IPO，并领导ASX和纳斯达克财务报告。此前，Chaponnel先生担任过多个职位，包括特许会计、物流、零售的管理职位，以及Construction的首席财务官职位，之后进入医疗保健。他是澳大利亚和新西兰注册会计师的成员。
Andrew Chaponnel,has around 25 years of experience in finance roles including 11 years with Mesoblast, initially as the Group Financial Controller (6 years), then as Head of Finance (3 years) and now as interim Chief Financial Officer for the past two years. As part of Mesoblast Group finance leadership he has been integral to the implementation and maintenance of Mesoblast Limited borrowing arrangements, various strategic partnerships, equity placements, the NASDAQ IPO and leads both ASX and NASDAQ financial reporting. Previously Mr. Chaponnel has held several roles including management roles in chartered accountancy, logistics, retail and a CFO role within construction before moving into Healthcare. He is a member of the Chartered Accountants of Australia & New Zealand.- Andrew Chaponnel拥有约25年的财务经验，包括在Mesoblast工作9年，最初担任集团财务总监6年，过去3年担任财务主管。作为Mesoblast Group Finance Leadership的一部分，他一直参与执行和维护我们的借款安排，各种战略合作伙伴关系，股权配售，纳斯达克IPO，并领导ASX和纳斯达克财务报告。此前，Chaponnel先生担任过多个职位，包括特许会计、物流、零售的管理职位，以及Construction的首席财务官职位，之后进入医疗保健。他是澳大利亚和新西兰注册会计师的成员。
- Andrew Chaponnel,has around 25 years of experience in finance roles including 11 years with Mesoblast, initially as the Group Financial Controller (6 years), then as Head of Finance (3 years) and now as interim Chief Financial Officer for the past two years. As part of Mesoblast Group finance leadership he has been integral to the implementation and maintenance of Mesoblast Limited borrowing arrangements, various strategic partnerships, equity placements, the NASDAQ IPO and leads both ASX and NASDAQ financial reporting. Previously Mr. Chaponnel has held several roles including management roles in chartered accountancy, logistics, retail and a CFO role within construction before moving into Healthcare. He is a member of the Chartered Accountants of Australia & New Zealand.
- Justin Horst
Justin Horst拥有18年的临床细胞疗法制造和行业发展经验。在过去的八年中，他一直担任Mesoblast’；的制造副主管，负责化学、制造和制造过程的控制。在加入Mesoblast之前，Horst先生在Lonza Walkersville Inc.工作了10年，在制造、项目管理和业务开发集团担任多个高级职位。
Justin Horst,has 18 years of experience in clinical cell therapy manufacturing and industry development. During the past eight years, he has been Mesoblast's Deputy Head of Manufacturing, with accountability for chemistry, manufacturing and control of the manufacturing processes. Before joining Mesoblast, Mr. Horst was at Lonza Walkersville Inc. for 10 years, holding numerous senior level positions within the manufacturing, project management, and business development groups. At Lonza, he was instrumental in the establishment of the contract manufacturing business, and managed multiple manufacturing teams supporting numerous custom supply processes. Mr. Horst obtained his B.S. in Biology from Towson University in Maryland.- Justin Horst拥有18年的临床细胞疗法制造和行业发展经验。在过去的八年中，他一直担任Mesoblast’；的制造副主管，负责化学、制造和制造过程的控制。在加入Mesoblast之前，Horst先生在Lonza Walkersville Inc.工作了10年，在制造、项目管理和业务开发集团担任多个高级职位。
- Justin Horst,has 18 years of experience in clinical cell therapy manufacturing and industry development. During the past eight years, he has been Mesoblast's Deputy Head of Manufacturing, with accountability for chemistry, manufacturing and control of the manufacturing processes. Before joining Mesoblast, Mr. Horst was at Lonza Walkersville Inc. for 10 years, holding numerous senior level positions within the manufacturing, project management, and business development groups. At Lonza, he was instrumental in the establishment of the contract manufacturing business, and managed multiple manufacturing teams supporting numerous custom supply processes. Mr. Horst obtained his B.S. in Biology from Towson University in Maryland.
- Niva Sivakumar
Niva Sivakumar于2014年加入Mesoblast的法律团队，是该公司知识产权委员会的成员。此前，她曾在大型律所Dentons担任企业和商业团队的高级助理，并在K & L Gates担任高级律师。Sivakumar女士拥有墨尔本大学的商业/法律学位。
Niva Sivakumar,joined Mesoblast's legal team in 2014 and is a member of the company's Intellectual Property Committee. Previously, she was a senior associate in the corporate and commercial teams at major law firm, Dentons, and a senior lawyer at K&L Gates. Ms. Sivakumar has a Commerce/Law degree from the University of Melbourne.- Niva Sivakumar于2014年加入Mesoblast的法律团队，是该公司知识产权委员会的成员。此前，她曾在大型律所Dentons担任企业和商业团队的高级助理，并在K & L Gates担任高级律师。Sivakumar女士拥有墨尔本大学的商业/法律学位。
- Niva Sivakumar,joined Mesoblast's legal team in 2014 and is a member of the company's Intellectual Property Committee. Previously, she was a senior associate in the corporate and commercial teams at major law firm, Dentons, and a senior lawyer at K&L Gates. Ms. Sivakumar has a Commerce/Law degree from the University of Melbourne.
- Paul Hughes
Paul Hughes于2019年2月开始与Mesoblast合作，自2020年12月起担任公司全球企业传播主管。他在麦格理银行和澳大利亚联邦银行等公司担任投资银行家和企业顾问，拥有丰富的背景。休斯先生拥有墨尔本莫纳什大学的药学学士和商业学士学位（银行和金融）。
Paul Hughes,began working with Mesoblast in February 2019 and has served as the Company's Global Head of Corporate Communications since December 2020. He has an extensive background as an investment banker and corporate advisor for firms including Macquarie Bank and Commonwealth Bank of Australia. Mr. Hughes has a Bachelor of Pharmacy and Bachelor of Business (Banking & Finance) from Monash University, Melbourne.- Paul Hughes于2019年2月开始与Mesoblast合作，自2020年12月起担任公司全球企业传播主管。他在麦格理银行和澳大利亚联邦银行等公司担任投资银行家和企业顾问，拥有丰富的背景。休斯先生拥有墨尔本莫纳什大学的药学学士和商业学士学位（银行和金融）。
- Paul Hughes,began working with Mesoblast in February 2019 and has served as the Company's Global Head of Corporate Communications since December 2020. He has an extensive background as an investment banker and corporate advisor for firms including Macquarie Bank and Commonwealth Bank of Australia. Mr. Hughes has a Bachelor of Pharmacy and Bachelor of Business (Banking & Finance) from Monash University, Melbourne.